Search clinical trials for: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)

Total 835 results

National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

HIV Infections

South Africa, Uganda, Zimbabwe
Gilead Sciences

Completed

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Chronic Hepatitis B

United States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
University of Washington
Bill and Melinda Gates Foundation

Completed

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)

HIV Infections | HIV-1 Infections

Kenya, Uganda
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (VESTED)

HIV Infections

United States, South Africa, Thailand, Botswana, Brazil, Tanzania, Zimbabwe, India, Uganda
MRC/UVRI and LSHTM Uganda Research Unit
London School of Hygiene and Tropical Medicine; Assistance Publique - Hôpitaux... and other collaborators

Not yet recruiting

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa (MOBILEMEN)

HIV
Kirby Institute
Government of Western Australia, Department of Health; Western Australia AIDS...

Completed

Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial (PrEPIT-WA)

HIV Prevention

Australia
Duke University

Completed

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (PHI04)

HIV

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
CDC Foundation
Gilead Sciences

Unknown

Sustainable Healthcenter Implementation PrEP Pilot Study (SHIPP)

HIV Preexposure Prophylaxis | HIV Chemoprophylaxis

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

HIV Infections
Kirby Institute

Completed

PrEP Demonstration Project (PRELUDE Study) (PRELUDE)

HIV

Australia
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

HIV Infections

South Africa
FHI 360

Completed

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

HIV Infections

Kenya, South Africa, Tanzania
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
ANRS, Emerging Infectious Diseases

Recruiting

Prevention of HIV in "Île-de-France" (ANRS-PREVENIR)

HIV Infections

France
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
National Institute of Allergy and Infectious Diseases...
Gilead Sciences

Completed

Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

HIV Infections

Malawi, Zimbabwe, South Africa, Uganda
Professor Francois Venter

Completed

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE)

HIV-1 Infection

South Africa
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
ANRS, Emerging Infectious Diseases
Gilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaborators

Not yet recruiting

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (SimpPrEP)

HIV/AIDS

France, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission (OCTANE)

HIV Infections

South Africa, Botswana, Kenya, Malawi, Uganda, Zambia, Zimbabwe
Children's Hospital of Philadelphia
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Not yet recruiting

Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome (RTI in AGS)

Aicardi Goutières Syndrome

United States
MRC [ycm]

Completed

Pre-exposure Option for Reducing HIV in the UK.(PROUD) (PROUD)

HIV

United Kingdom
Philadelphia Fight

Completed

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

HIV

United States
Kirby Institute

Completed

Expanded PrEP Implementation in Communities in NSW (EPIC-NSW)

HIV | STI

Australia
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
Gilead Sciences

Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada (SWIFT)

HIV Infection

United States, Puerto Rico, Canada
Johns Hopkins University

Withdrawn

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

Pregnancy | HIV-1-infection
Gilead Sciences

Completed

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Hepatitis B

Canada, Germany, Turkey, United States, Greece, New Zealand, Hungary, Romania, Bulgaria, Serbia, Austria, Poland, Czech Republic, Spain
Duke University
The Emmes Company, LLC

Recruiting

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana (BMS02)

HIV Infections | Lactating Women on Select DOI | Breastmilk Fed Infants of Mothers on Select DOI

South Africa
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

HIV Infections

Peru, Brazil, South Africa, Uganda, Botswana, Haiti, Zambia, Zimbabwe
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

HIV Infections

United States, Puerto Rico
Abbott
Merck Sharp & Dohme LLC

Completed

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) (PROGRESS)

Human Immunodeficiency Virus Infection

United States, Canada, France, Italy, Poland, Puerto Rico, Spain
Eastern Virginia Medical School
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor

HIV/AIDS | Adherence, Medication | Drug Use

United States
Oak Crest Institute of Science
Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaborators

Active, not recruiting

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) (PrEP-Pod-IVR)

HIV Prevention

United States
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Prism Health North Texas
Merck Sharp & Dohme LLC

Withdrawn

Doravirine and Weight Gain in Antiretroviral Naive (DAWN)

Obesity | Metabolic Syndrome | Body Weight Changes | Human Immunodeficiency Virus | Fasting | Minority Health | ART | BMD

United States
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences
HIV Prevention Trials Network

Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102) (PURPOSE 3)

Pre-Exposure Prophylaxis of HIV Infection

United States

Search clinical trials for: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations